would like to highlight International Stem Cell Corporation
), researching the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The company is focused on using these stem cells to treat diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells or tissue.
In the company’s news,
International Stem Cell Corp. (OTCQB: ISCO) builds shareholder value through the development of restorative medicine using stem cell technology. Through its innovative parthenogenesis technology, the company makes use of human stem cells from unfertilized oocytes (eggs), bypassing common ethical controversy that accompanies the destruction of the viable human embryo. Additionally, the company works with subsidiaries Lifeline Skin Technology and Lifeline Skin Care in the area of skin rejuvenation on a product that contains a nano-compound that facilitates the replenishment of the skin’s texture and elasticity.
Evidence of the company’s resolve to be a leader in the field of restorative medicine can be found in a recent partnership with The Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement calls for the team to launch Phase I/IIa clinical trials research on the effects of human parthenogenetic stem cells in people with Parkinson’s disease.
The credibility The Florey Institute brings to ISCO’s mission to build shareholder value cannot be understated. The Florey Institute of Neuroscience and Mental Health is one of the world’s leading brain research centers, employing a staff of over 500. The center’s scientists comprise the largest neuroscience research team in Australia. Its work is conducted on a range of serious diseases, including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, traumatic brain and spinal cord injury, depression, multiple sclerosis, Huntington’s disease, motor neuron disease, schizophrenia, mental illness and addiction. Further, The Florey is viewed by many as a world leader in imaging technology, stroke rehabilitation and epidemiological studies.
The company’s human cell culture products are made up of adult stem cells and reagents for regenerative medicine aiding in the study of prostate disease, human renal and bladder diseases, human corneal cells present in corneal disease and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. ISCO markets and sells skincare products through its website, channel sales, distributors and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corp. was founded in 2001 and is headquartered in Carlsbad, California.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.